pleased to share an open access link to the 2 year follow up report of the EPCORE-NHL1 trial (#epcoritamab in 3L+ LBCL) est 2 year PFS / OS rates 27.8 / 44.6% no CRS on repriming G3+ infections highest in first 12 weeks (10.8%) #lymSM Leukemia Journal nature.com/articles/s4137…

Kudos to my mentee Daniel Fasser on his first manuscript: Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era tandfonline.com/doi/citedby/10… #lymSM North Metropolitan Health Service UWA Research #MDscholarlyactivity

looking forward to this #ASH24 educational symposium, do join us there!

if you need a distraction from #USElection2024 I am happy to report #ASH24 abstracts are available to review as of 15 minutes ago...

#ASH24 mantle cell lymphoma abstracts I'm looking forward to: 1. ENRICH ash.confex.com/ash/2024/webpr… n=397 🇬🇧led academic ph3 RCT ibrutinib rituximab vs BR/RCHOP IR superior to R-chemo (HR 0.69) though this differed by chemo arm (HR 0.37 RCHOP, 0.91 BR). Practice changing? #lymSM

#ASH24 Mats Jerkeman phase 2 Nordic trial of acala rituximab in TN-MCL ash.confex.com/ash/2024/webpr… n=81, MRD adapted design for non-high risk biology TP53mut 24%, Ki-67>30% 22% median FU 15 months, 1 year PFS 86.5% (69% for TP53mut). Expect this to be better tolerated than IR #lymSM

#ASH24 continuing a theme Steven OASIS-2 ash.confex.com/ash/2024/webpr… RCT of ibrutinib+CD20 vs I+CD20+venetoclax. n=102 enrolled to date, interim futility analysis MRD/ddPCR. Unclear which CD20 was used... but MRD negative rates high in both arms, enrolment ongoing #lymSM

#ASH24 RWD for MCL post brexu-cel failure🇺🇸 analysis ash.confex.com/ash/2024/webpr… n=306 from 9 sites (!) med PFS 2.3m OS 5.4m from PD ☹️ORR for pirto 31%, chemo 25% ven 20%, bispecifics 60% (albeit non-randomized/small numbers). Novel combinations needed... #lymSM

#ASH24 🇫🇷 DESCART analysis of RWD post CART MCL v. similar outcomes to the US experience ash.confex.com/ash/2024/webpr… n=178 med PFS 2m OS 5.8m respectively emphasising that much work still to be done here #lymSM

Pleased to share this important update on behalf of co-investigators: epcoritamab in 3L+ large B-cell lymphoma, durable CRs suggesting potential cure fraction #lymSM published in Leukemia Journal x.com/sn_oncology/st…

Thanks for highlighting this work and kudos Ross Salvaris NLPHL always presents an interesting management challenge. Much work to be done! Haematologica #lymSM

I'm with you here GC. Not many NLPHL patients who can't manage R-CVP (but if they couldn't then R mono is reasonable) #lymSM

Kudos Adrian Minson Michael Dickinson Haematology Peter MacCallum CC & Royal Melbourne for leading this excellent trial in high risk DLBCL #lymSM #ASH24

the practice changing STARGLO phase 3 trial demonstrating OS superiority for glofitamab-GemOx over R-GemOx in r/r DLBCL published today in The Lancet erudite commentary from Anna Sureda Astrid Pavlovsky #lymSMfree access via this link: authors.elsevier.com/c/1k60aV-4XOujG

Kudos to my fellow Brian Grainger on this review just out in Haematologica We highlight new and emerging data for novel therapeutics in post BTK inhibitor mantle cell lymphoma #lymSM North Metropolitan Health Service Open access link below: haematologica.org/article/view/1…

Thanks Australasian Leukaemia & Lymphoma Group (ALLG) team for organising another great scientific meeting. Wonderful to see all of the great work being done by 🇦🇺🇳🇿 investigators working tirelessly to improve outcomes for patients with blood cancers. And always great to connect with colleagues in person!

Dear friends and colleagues, let's continue the conversation on the channel next door... bsky.app/profile/chanch…

Excellent work to my fellow Brian Grainger and Phil Thompson on this review just out in Blood Journal Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia. ashpublications.org/blood/article-…